Vaxil Bio Ltd.

(VXL:PUR)

By |

Profile

Vaxil Bio Ltd is a Canada based immuno-oncology biotechnology company. It is principally engaged in research and development of the ImMucin vaccine to treat cancer. ImMucin is the company's immunotherapy product. The organization is focused on developing novel immunotherapies including neoantigen-like peptide products, and antibodies to treat cancer and infectious diseases. Its VaxHit platform allows identification, isolation, and production of specific antigen-based immunotherapy products.

Contact Information

Website: vxlbio.com
Main Phone: +1 416 227-9667
Address: 4576 Yonge Street
Address 2: 6th Floor
State: ON
City / Town: Toronto
Country: CAN
Postal Code: M2N 6N4

Issuer Information

Exchange: CDX
CEO: Isaac Benjamin Maresky
NAICS: Pharmaceutical Preparation Manufacturing(325412)
$ 0.03 $ 0. (0.00%)
Last Price 0.03 Change $ 0. Change % 0.00 Tick N/A
Bid 0.025 Bid Size 60,000.00 Ask 0.035 Ask Size 90,000.00
Open 0.03 High 0.03 Low 0.03 Prev Close 0.03
Last Trade Volume 8,000 52 Wk Hi 0.22 52 Wk Low 0.03
Market Cap 2.7 mi Ex-Div Date N/A Div Rate N/A Yield N/A
Shares 88,929,447.00 EPS (TTM) -0.04 PE Ratio N/A Exchange TSXV